- Home
- GRF vs AIFF Comparison
GRF vs AIFF Comparison
Compare GRF & AIFF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRF
- AIFF
- Stock Information
- Founded
- GRF 1989
- AIFF 2006
- Country
- GRF United States
- AIFF United States
- Employees
- GRF N/A
- AIFF N/A
- Industry
- GRF Finance/Investors Services
- AIFF
- Sector
- GRF Finance
- AIFF
- Exchange
- GRF Nasdaq
- AIFF NYSE
- Market Cap
- GRF 38.9M
- AIFF 41.5M
- IPO Year
- GRF N/A
- AIFF N/A
- Fundamental
- Price
- GRF $9.77
- AIFF $2.92
- Analyst Decision
- GRF
- AIFF
- Analyst Count
- GRF 0
- AIFF 0
- Target Price
- GRF N/A
- AIFF N/A
- AVG Volume (30 Days)
- GRF 3.0K
- AIFF 1.5M
- Earning Date
- GRF 01-01-0001
- AIFF 08-18-2025
- Dividend Yield
- GRF 3.70%
- AIFF N/A
- EPS Growth
- GRF N/A
- AIFF N/A
- EPS
- GRF 1.16
- AIFF N/A
- Revenue
- GRF N/A
- AIFF $139,000.00
- Revenue This Year
- GRF N/A
- AIFF N/A
- Revenue Next Year
- GRF N/A
- AIFF N/A
- P/E Ratio
- GRF $8.15
- AIFF N/A
- Revenue Growth
- GRF N/A
- AIFF N/A
- 52 Week Low
- GRF $7.93
- AIFF $1.86
- 52 Week High
- GRF $10.19
- AIFF $17.20
- Technical
- Relative Strength Index (RSI)
- GRF 49.55
- AIFF 44.02
- Support Level
- GRF $9.76
- AIFF $2.70
- Resistance Level
- GRF $9.82
- AIFF $3.77
- Average True Range (ATR)
- GRF 0.04
- AIFF 0.25
- MACD
- GRF -0.01
- AIFF -0.02
- Stochastic Oscillator
- GRF 42.50
- AIFF 20.56
About GRF Eagle Capital Growth Fund Inc.
Eagle Capital Growth Fund Inc is a diversified closed-end investment company. The fund's objective is long-term growth utilizing the concept of total return for selecting investments. It seeks to achieve its investment objectives by investing predominantly in U.S. issuer common stock by giving preference to high-quality companies, where high quality denotes substantial operating income margins, high returns on capital, and robust balance sheets.
About AIFF FIREFLY NEUROSCIENCE INC
Firefly Neuroscience Inc is an AI company developing neuroscientific solutions that improve outcomes for patients with mental illnesses and cognitive disorders. It is focused on the commercialization of its Brain Network Analytics (BNA) software platform (the "BNA Platform")and the discovery and clinical development of biomarkers that support outcomes for people suffering from mental illnesses and cognitive disorders. The Company has one reportable segment: the BNA platform. The Company derives revenue from North America.